Danhof and colleagues co-express an adapter CAR in addition to an anti-lymphoma CAR to allow for ‘add-on’ modular adapter-mediated redirection towards additional tumor targets. This strategy counters antigen-negative relapse, a major resistance mechanism to CAR T cell therapy in lymphoma.